Parkwalk ads

🚀 Thrilled to launch our annual Equity Investment into Spinouts report 2025 in conjunction with Beauhurst. The report reveals 2024 was a record year for spinout investment with £3.35bn in funding! Parkwalk has once again been named the most active investor in UK university spinouts, reflecting our deep expertise and commitment to backing world-class innovation. Moray Wright, CEO of Parkwalk, said: “Spinouts are the future of this economy. It is where the UK has real comparative strength – capitalising on our world-leading research base. The companies raising record sums of investment in 2024 are tackling the biggest challenges of our time - from climate change to AI and healthcare. With the right policy environment, including long-term support for the Enterprise Investment Scheme and full implementation of the Mansion House reforms, we can ensure that the UK fully leverages its potential in frontier innovation.” Together with our parent company IP Group plc, we backed 54 spinouts in 2024, making the Group the UK’s biggest investor in the sector. The report has insight and analysis across spinout investment from the verticals driving growth to the regions and universities leading the league tables. Link to the full report in the comments 👇

🚀 Parkwalk, the UK’s leading growth EIS fund manager with 180+ investments, has teamed up with Northern Gritstone to launch a new EIS fund. This fund offers investors access to a diverse portfolio of early-stage companies from the Northern Arc’s top research universities – Leeds, Liverpool, Manchester and Sheffield – all with the potential for Enterprise Investment Scheme tax reliefs. Take 2 mins to learn more about the risks: https://lnkd.in/eg6gmrHd Tax reliefs dependent on individual investor circumstances. June 2025 Parkwalk Advisors is authorised and regulated by the FCA: 502237

Parkwalk, the UK’s leading growth Enterprise Investment Scheme fund manager with 180+ investments, has teamed up with Northern Gritstone to launch a new EIS fund. 🚀 This fund offers investors access to a diversified portfolio of early-stage companies from the Universities of Leeds, Liverpool, Manchester and Sheffield, all with the potential for EIS tax reliefs. Take 2 mins to learn more about the risks: https://lnkd.in/eg6gmrHd Tax reliefs dependent on individual investor circumstances. June 2025 Parkwalk is authorised and regulated by the FCA: 520237

Calling Manchester alumni — support innovation from your alma mater! 🎓 Parkwalk’s new EIS fund, in collaboration with Northern Gritstone, invests in early-stage spinouts from the Northern Arc universities including the University of Manchester. 💸 Invest in the next wave of deeptech spinouts from your region and benefit from potential Enterprise Investment Scheme tax reliefs. Take 2 mins to learn more about the risks: https://lnkd.in/eg6gmrHd Tax reliefs dependent on individual investor circumstances. June 2025 Parkwalk Advisors is authorised and regulated by the FCA: 502237

Calling Liverpool alumni — support innovation from your alma mater! 🎓 Parkwalk’s new EIS fund, in collaboration with Northern Gritstone, invests in early-stage spinouts from the Northern Arc universities including the University of Liverpool. 💸 Invest in the next wave of deeptech spinouts from your region and benefit from potential Enterprise Investment Scheme tax reliefs. Take 2 mins to learn more about the risks: https://lnkd.in/eg6gmrHd Tax reliefs dependent on individual investor circumstances. June 2025 Parkwalk Advisors is authorised and regulated by the FCA: 502237

Calling Sheffield alumni — support innovation from your alma mater! 🎓 Parkwalk’s new EIS fund, in collaboration with Northern Gritstone, invests in early-stage spinouts from the Northern Arc universities including the University of Sheffield. 💸 Invest in the next wave of deeptech spinouts from your region and benefit from potential Enterprise Investment Scheme tax reliefs. Take 2 mins to learn more about the risks: https://lnkd.in/eg6gmrHd Tax reliefs dependent on individual investor circumstances. June 2025 Parkwalk Advisors is authorised and regulated by the FCA: 502237